Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Desirial Plus is a sterile, injectable gel medical device developed by Laboratoires VIVACY, primarily used in aesthetic and functional gynecology. It is composed of cross-linked hyaluronic acid and mannitol, formulated using the proprietary Inter-Penetrated Cross-linked Networks (IPN)-like technology. The product is specifically indicated for the treatment of moderate to severe hypotrophy or atrophy of the labia majora and vulva, as well as vulvovaginal dryness and associated discomfort. By acting as a volumizing and hydrating agent within the extracellular matrix of vulvovaginal tissues, it restores volume and improves tissue hydration. It is also utilized to enhance the aesthetic appearance of the labia majora and has applications in addressing female sexual dysfunction. The gel is administered via subcutaneous injection by healthcare professionals, with clinical effects typically lasting up to 12 months.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Desirial Plus.